Crackdown On Bad Regenerative Medicine Could Benefit Gene Therapy
Executive Summary
US FDA to offer series of guidances on regenerative product development – and declares gene therapies eligible for RMAT – as enforcement against 'unscrupulous actors' continues.
You may also be interested in...
US FDA’s Stem Cell Clinic Enforcement Takes A Hit With Loss In California Case
Federal judge denies government’s request to permanently enjoin California stem cell clinic from administering unapproved stromal vascular stem cell treatments, concluding they are not ‘drugs’ under the FD&CA. The ruling runs counter to a decision in a similar case involving a Florida stem cell clinic.
US FDA’s Stem Cell Clinic Enforcement Takes A Hit With Loss In California Case
Federal judge denies government’s request to permanently enjoin California stem cell clinic from administering unapproved stromal vascular stem cell treatments, concluding they are not ‘drugs’ under the FD&CA. Ruling runs counter to decision in similar case involving a Florida stem cell clinic.
Unapproved Cell/Tissue Product Enforcement Discretion Ends; How Hard Will US FDA Crack Down?
Entities that already have received letters from the agency raising concerns about marketing unapproved products may not necessarily be the first to face enforcement actions, CBER official says.